BCMA纳米抗体CAR T细胞疗法在复发或难治性浆细胞骨髓瘤中的疗效与安全性
本研究探索了基于双纳米抗体VHH靶向BCMA的S103 CAR T细胞疗法治疗复发或难治性浆细胞骨髓瘤。27例患者(含4例浆细胞白血病、1例间变性浆细胞骨髓瘤)接受治疗,1个月总缓解率96.3%,3个月升至100%,中位缓解持续时间11个月。结论认为该疗法缓解率高且安全性可控。
要点
- S103 CAR T细胞采用双纳米抗体VHH靶向BCMA,治疗27例复发或难治性浆细胞骨髓瘤。
- 1个月总缓解率96.3%(26/27),完全缓解+非常好的部分缓解率59.2%(16/27)。
- 3个月总缓解率100%(27/27),完全缓解+非常好的部分缓解率81.5%(22/27)。
核心结论
- 基于双纳米抗体VHH靶向BCMA的CAR T细胞疗法在复发或难治性浆细胞骨髓瘤中显示高总缓解率和可控的安全性。
研究设计与样本
- 研究纳入27例复发或难治性浆细胞骨髓瘤患者接受S103 CAR T细胞治疗,其中4例为浆细胞白血病,1例为间变性浆细胞骨髓瘤。
- 11例患者有多发髓外病变,11例有高危遗传学异常,包括4例TP53突变。
- 该试验在ClinicalTrials.gov注册,注册号为NCT04447573。
主要发现
- CAR T细胞输注后1个月,总缓解率为96.3%(26/27),完全缓解+非常好的部分缓解率为59.2%(16/27)。
- 3个月随访时,总缓解率升至100%(27/27),完全缓解+非常好的部分缓解率为81.5%(22/27)。
- 中位缓解持续时间为11个月(范围2-36个月)。
- 1年总生存率为61.1%,无进展生存率为57.2%。
临床怎么用
- 作者认为,基于双纳米抗体VHH靶向BCMA的CAR T细胞疗法在复发或难治性浆细胞骨髓瘤患者中显示高总缓解率和可控的安全性,包括伴有髓外病变、高危细胞遗传学异常、浆细胞白血病或间变性浆细胞瘤等高危特征的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has demonstrated promising therapeutic efficacy in relapsed or refractory (R/R) multiple myeloma. However, distinct CAR T-cell constructs exhibit varying therapeutic outcomes. As the antigen-recognition domain, nanobodies offer a small, stable, single-domain structure with enhanced affinity and specificity compared with conventional single-chain variable fragments. We explored the use of nanobody-based BCMA(S103) CAR T-cell therapy for R/R plasma cell myeloma. The CAR construct incorporates dual-nanobody variable domain of the heavy chain of heavy chain antibody (VHHs) targeting BCMA. A cohort of 27 patients was treated with S103 CAR T-cell therapy, which included 4 patients of plasma cell leukemia, and 1 patient of anaplastic plasma cell myeloma. Eleven patients had multiple extramedullary lesions, and 11 patients exhibited high-risk genetic abnormalities, including 4 with TP53 mutations. One month after CAR T-cell infusion, the overall response rate (ORR) was 96.3% (26/27), with a complete response (CR) + very good partial response (VGPR) rate of 59.2% (16/27). At the 3-month follow-up, the ORR increased to 100% (27/27), with a CR + VGPR rate of 81.5% (22/27). The median duration of remission was 11 months (range, 2-36 months). The 1-year overall survival rate was 61.1%, and progression-free survival was 57.2%. In conclusion, BCMA CAR T-cell therapy, utilizing dual-nanobody VHHs targeting BCMA, demonstrates a high ORR and manageable safety profile in treating patients with R/R plasmacytic myeloma, including those with high-risk features such as extramedullary lesions, high-risk cytogenetic abnormalities, plasma cell leukemia, or anaplastic plasmacytoma. This trial was registered at www.ClinicalTrials.gov as #NCT04447573.
引用
- Zhang XG, Wang L, Yang J, et al. Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma. Blood Adv. 2025. PMID: 40569697. doi:10.1182/bloodadvances.2025016322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。